Icahn School of Medicine at Mount Sinai
ASH 2023 Insights: "Venetoclax Improves Response Rates But Not Survival in Pts With CMML Treated With Hypomethylating Agents"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Douglas Tremblay
By
Insights from 2023 ASH Annual Meeting
FEATURING
Douglas Tremblay
Login to view comments.
Click here to Login